Survey on antibiotic regimens for necrotizing enterocolitis prescribed by Chinese pediatricians in 2020

Zhongyao Zhang, Yu He, Zhengli Wang, Lei Bao, Yuan Shi, Luquan Li

ABSTRACT

Background Necrotizing enterocolitis (NEC) is a serious intestinal inflammatory disease in neonates, and intravenous antibiotics constitute the main therapeutic strategy. Studies have shown that substantial variation in the selection of antibiotic regimens for NEC remains in many countries. The variability in antibiotic therapy selection in China is unclear.

Methods A cross-sectional study using an online questionnaire regarding antibiotic regimens for NEC was conducted among pediatricians working in tertiary hospitals in China.

Results A total of 284 pediatricians from 29 provinces completed the survey; 37.9% of them administered one antibiotic, 56.7% administered two antibiotics and 2.4% administered three antibiotics. The top three single-antibiotic regimens for NEC were beta-lactamase inhibitors (n=66, 41.5%), carbapenems (n=46, 28.9%) and cephalosporins (n=33, 20.8%). Twenty combinations of two antibiotics were identified, and the top three combinations were beta-lactamase inhibitors and antianaerobic agents (n=49, 19.6%), carbapenems and glycopeptides (n=42, 16.8%), and cephalosporins and antianaerobic agents (n=37, 14.8%). Regarding the therapeutic duration of antibiotic treatment, 77.5% (n=220) of the pediatricians chose 5–10 days for stage II NEC, and 79.6% (n=226) chose 7–14 days for stage III NEC. Forty-three percent (n=122) of the respondents preferred to use carbapenems when NEC was diagnosed, and 83.3% (n=135) adjusted the antibiotics to carbapenems if a patient’s medical condition deteriorated or if the therapeutic efficacy was poor.

Conclusion This survey revealed that carbapenems were the most common antibiotics selected when NEC was diagnosed or a patient’s condition deteriorated, but the duration of the course of treatment for NEC varied substantially among doctors.

INTRODUCTION

Necrotizing enterocolitis (NEC) is an acquired neonatal intestinal disease characterized by severe inflammation attributed to a variety of factors. NEC is a major cause of morbidity and mortality in the neonatal period. The incidence rate of NEC is 7%–13% in preterm infants younger than 28 weeks of gestational age. Overall mortality rates due to NEC range from 15% to 30%.

Survivors can have significant sequelae, including short-term outcomes, such as intestinal stenosis, short gut syndrome and intestinal failure, and long-term sequelae, such as growth retardation and severe behavioral and neurodevelopmental delays. The current treatment strategy for NEC is a combination of medical and surgical therapies. Non-operative management typically includes bowel rest, gastrointestinal decompression, broad-spectrum intravenous antibiotics, and intravenous nutrition. Antibiotic treatment is the most important therapeutic strategy. The selection of antibiotics differs in different regions despite the issuance of the American Surgical Infection Society Guidelines in 2010. In addition, a Cochrane systematic review indicated that there remains a lack of adequate evidence to recommend a particular antibiotic regimen for NEC, and there is still high variability among the

Summary box

What is already known about this subject

► Necrotizing enterocolitis (NEC) is a serious intestinal inflammatory disease in neonates.
► Intravenous antibiotics constitute the main therapeutic strategy.
► The selection of antibiotic regimens for NEC varies in many countries, and the preferences of Chinese pediatricians are not clear.

What are the new findings

► Carbapenems were the most common antibiotics selected if NEC was diagnosed or if a patient’s condition deteriorated.
► The duration of the course of treatment for NEC varied substantially among doctors.

How might it impact on clinical practice in the foreseeable future

► There is no unified antibiotic treatment regimen for NEC, and it is necessary to carry out multicenter research to provide the basis for the formulation of relevant guidelines for the antibiotic treatment of NEC in the future.
antibiotic therapies administered.\textsuperscript{9–11} Blackwood’s single-center survey showed that up to 22 different antibiotics were used before surgery for NEC.\textsuperscript{11} An international survey conducted in 29 countries indicated that the majority (67\%) of surgeons chose to treat NEC with a combination of two or more antibiotics.\textsuperscript{10} A retrospective study found that infants with NEC treated with medical (vs surgical) therapy were more likely to be treated with metronidazole, whereas those treated with surgical (vs medical) therapy were more likely to receive vancomycin.\textsuperscript{12} Selected antibiotic regimens vary widely among different specialties and geographic locations\textsuperscript{10–13}; however, reports from China are rare, the preferences of Chinese pediatricians in the selection of antibiotics are not clear. Furthermore, there is no clear guideline outlining an optimal therapy strategy for NEC.

The aim of the present study was to investigate the current status of antibiotic regimen selection for the treatment of NEC in China via an online questionnaire. The goals were to obtain expert consensus, to standardize treatment and to update therapeutic recommendations.

\section*{METHODS}

\subsection*{Participants}
The study objects included pediatricians in tertiary hospitals in China, who were attending physicians or had more senior positions.

\subsection*{Questionnaire design}
A cross-sectional study was conducted to design the NEC management questionnaire. The questionnaire was divided into three parts: baseline information, NEC diagnosis and NEC treatment. The diagnosis of NEC was based on Bell staging.\textsuperscript{14} The stage II NEC criteria include clinical manifestations, such as abdominal distension; vomiting or blood in the stool (with an absence of fissure); and pneumatosis intestinalis or portal vein gas on X-ray or ultrasound examination. Stage III NEC is diagnosed according to the above criteria plus imaging findings of pneumoperitoneum or a large amount of ascites or the need for surgery when medical therapy is not effective within 48 hours. We sent the questionnaire via a web-based tool (www.wjx.cn) to participants. The questionnaire was completed online on mobile phones or computers, and each computer or mobile phone could only be used to complete the questionnaire once.

\subsection*{Data collection}
Data were collected by an online questionnaire platform (www.wjx.cn). A large-scale network academic conference on neonatal NEC was organized. The participating physicians from tertiary hospitals across the country voluntarily completed the questionnaire through the published links. Thirty-nine participants were excluded because the antibiotic treatment practices were not clear (the type of antibiotic used was not specified; thus, it could not be classified). We attempted to contact them all by email, but no one replied.

\subsection*{Statistical analysis}
All analyses were performed with SPSS (V.17; SPSS). Categorical variables are expressed as number and percentages (%). The $\chi^2$ test was used for comparisons between groups, and $p<0.05$ was considered statistically significant. Data were plotted with GraphPad Prism (V.8.0).

\section*{RESULTS}

\subsection*{Baseline information analyses}
The survey was administered from March to April 2020. A total of 323 questionnaires were returned, of which 39 were excluded because the use of antibiotics was not clear (the type of antibiotic used was not specified; thus, it could not be classified). We attempted to contact them all by email, but no one replied.

\begin{table}[h]
\centering
\caption{Demographic information of 284 pediatricians}
\begin{tabular}{|l|l|l|}
\hline
Contents & n & Frequency (\%) \\
\hline
Educational attainment & & \\
Undergraduate & 1 & 0.4 \\
Bachelor’s degree & 125 & 44.0 \\
Master’s degree & 109 & 38.4 \\
Doctor’s degree & 49 & 17.3 \\
\hline
Title & & \\
Attending physician & 81 & 28.5 \\
Associate chief physician & 83 & 29.2 \\
Chief physician & 120 & 42.3 \\
\hline
Duration of clinical experience (y) & & \\
<10 & 48 & 16.9 \\
10–20 & 85 & 29.9 \\
>20 & 151 & 53.2 \\
\hline
Number of NEC cases received per year in your hospital & & \\
<50 & 222 & 78.2 \\
50–100 & 39 & 13.7 \\
100–200 & 13 & 4.6 \\
>200 & 10 & 3.5 \\
\hline
Can NEC surgery be performed in your hospital? & & \\
Yes & 109 & 38.4 \\
No & 175 & 61.6 \\
\hline
\end{tabular}
\end{table}

NEC, necrotizing enterocolitis.
respondents had a master’s degree or above. A total of 236 (83.1%) pediatricians had more than 10 years of clinical work experience, and 151 (53.2%) pediatricians had more than 20 years of experience.

**Antibiotic strategy selection**

When NEC was confirmed, 37.9% of the physicians selected one antibiotic, 56.7% selected a combination of two antibiotics, and 2.4% chose three antibiotics. Sixty-six (41.5%) physicians chose beta-lactamase inhibitors, 46 (28.9%) chose carbapenems, and 33 (20.8%) chose cephalosporins, followed by penicillins, oxacephems, and antianaerobic agents. The selection of antibiotics is shown in figure 1.

Figure 1 showed that beta-lactamase inhibitors and the other two antibiotics had relatively higher selection frequencies. Therefore, this study compared the selection of the top three most commonly selected antibiotics by pediatricians with different durations of clinical experience. The results indicated that there was no significant difference in the selection preferences among doctors with different durations of clinical experience (table 2).

A total of 20 combinations were reported. Forty-nine (19.6%) were combinations of beta-lactamase inhibitors and antianaerobic agents, 42 (16.8%) were combinations of carbapenems and glycopeptides, 37 (14.8%) were combinations of cephalosporins and antianaerobic agents, and 28 (11.2%) were combinations of cephalosporins and penicillins. The top nine most common antibiotic combinations are shown in figure 2. The 20 combinations of antibiotics are shown in online supplemental table 1.

Figure 2 showed that the selection frequencies of the top five antibiotics, such as beta-lactamase inhibitors and antianaerobic agents, were relatively high. Further comparison of the selections made by physicians with different durations of clinical experience showed no significant differences in the preferences for antibiotic combinations between the groups (table 3).

Some participants chose triple antibiotic therapy to treat NEC, including five reports of penicillins, cephalosporins, and antianaerobic agents; three reports of carbapenems, glycopeptides, and antianaerobic agents; and one report of beta-lactamase inhibitors/glycopeptides, antianaerobic agents, and cephalosporins.

**Antibiotic duration selection**

The durations of antibiotic therapy selected by the 284 participants for the treatment of stage II NEC are shown in figure 3. As shown in figure 3, 52.1% of the respondents chose 7–10 days, and similar proportions of the respondents chose 5–7 and 10–14 days. There was no significant difference in the duration of antibiotic courses selected by physicians with different seniority levels (online supplemental table 2).

The durations of antibiotic therapy selected for stage III NEC are shown in figure 3; 56.3% of the respondents chose 7–10 days, and 23.2% of the physicians chose 10–14 days. There was no significant difference among

---

**Table 2** Comparison of single agents selected by pediatricians with different seniority levels

<table>
<thead>
<tr>
<th>Medications, n (%)</th>
<th>&lt;10 y (n=28)</th>
<th>10–20 y (n=51)</th>
<th>&gt;20 y (n=66)</th>
<th>χ²</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-lactamase inhibitors</td>
<td>16 (57.1)</td>
<td>18 (35.3)</td>
<td>32 (48.5)</td>
<td>4.345</td>
<td>0.361</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>6 (21.4)</td>
<td>19 (37.3)</td>
<td>21 (31.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>6 (21.4)</td>
<td>14 (27.5)</td>
<td>13 (19.7)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
physicians with different seniority levels (online supplemental table 3).

**Adjustment of antibiotic treatment strategies**

This survey investigated the details of the choice of alternative antibiotics when the primary antibiotic was not effective (table 4). As shown in table 4, when NEC was confirmed, carbapenems were most commonly selected (43.0%, including single or combined use), followed by antianaerobic agents, including metronidazole, ornidazole, and clindamycin. Only 1.4% used antifungal agents as the first choice. When a patient’s condition worsens or the treatment effect is unsatisfactory, most physicians switch to carbapenems.

**DISCUSSION**

Selection of appropriate antibiotic regimens

Broad-spectrum antibiotic therapy is an important treatment for all infants with NEC. However, the current status of antibiotic treatment of NEC in China remains unclear because there have been no previous reports. This study is the first to investigate the antibiotic use strategies employed by Chinese physicians for the treatment of NEC. The questionnaire survey had a wide geographical distribution and high coverage. The respondents were 284 pediatricians working in 182 tertiary hospitals in 29 provinces of China, most of them had worked in clinical practice for over 10 years, and more than half of the subjects had worked for over 20 years. The respondents have rich clinical experience, and their opinions are generally representative.

Table 3 Comparison of the combinations of two antibiotics selected by physicians with different seniority levels

<table>
<thead>
<tr>
<th>Medications, n (%)</th>
<th>&lt;10 y (n=25)</th>
<th>10–20 y (n=50)</th>
<th>&gt;20 y (n=105)</th>
<th>( \chi^2 )</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLIs+AAAs</td>
<td>9 (36.0)</td>
<td>16 (32.0)</td>
<td>24 (22.9)</td>
<td>8.246</td>
<td>0.410</td>
</tr>
<tr>
<td>Carbapenems+GLPs</td>
<td>8 (32.0)</td>
<td>9 (18.0)</td>
<td>25 (23.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cephalosporins+AAAs</td>
<td>5 (20.0)</td>
<td>11 (22.0)</td>
<td>21 (20.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cephalosporins+PENs</td>
<td>0 (0)</td>
<td>8 (16.0)</td>
<td>20 (19.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbapenems+AAAs</td>
<td>3 (12.0)</td>
<td>6 (12.0)</td>
<td>15 (14.3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AAAs, antianaerobic agents; BLIs, beta-lactamase inhibitors; GLPs, glycopeptides; PENs, penicillins.

Based on the results of our questionnaire survey, 41.5% of the physicians chose beta-lactamase inhibitors, 28.9% chose carbapenems, and 20.8% chose cephalosporins to treat NEC among the single-antibiotic regimens. When combining antibiotics to treat NEC, beta-lactamase inhibitors and antianaerobic agents were the most frequently selected combination, followed by carbapenems and glycopeptides and cephalosporins and antianaerobic agents. There was no significant difference in the choice of NEC antibiotics by physicians with different durations of experience (p>0.05). In Europe and the USA, triple antibiotic regimens are often used to treat NEC, such as ampicillin, gentamicin, and metronidazole,9 12 whereas in China pediatricians mainly select combinations of two antibiotics, primarily those effective against Gram-negative bacilli and anaerobic bacteria, which means that the treatment of Gram-positive cocci may be inadequate. In addition, cephalosporins are still effective against anaerobic bacteria, and it is not entirely reasonable to combine cephalosporins with metronidazole. In this survey, although there were as many as 20 reported combinations of antibiotics, the appropriateness of these combinations deserves consideration. This suggests that further study on the optimal combination

Table 4 Adjustment of the antibiotic strategies for the treatment of NEC

<table>
<thead>
<tr>
<th>Group</th>
<th>Antibiotic regimen</th>
<th>Frequency, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Carbenpems as a first choice</td>
<td>122 (43.0)</td>
</tr>
<tr>
<td></td>
<td>Step up to carbapenems after deterioration</td>
<td>135 (83.3)</td>
</tr>
<tr>
<td>2</td>
<td>Glycopeptides as a first choice</td>
<td>54 (19.0)</td>
</tr>
<tr>
<td></td>
<td>Step up to glycopeptides after deterioration</td>
<td>48 (20.9)</td>
</tr>
<tr>
<td>3</td>
<td>AAAs (metronidazole/ornidazole/clindamycin) as a first choice</td>
<td>100 (35.2)</td>
</tr>
<tr>
<td></td>
<td>Add AAAs after deterioration</td>
<td>13 (7.1)</td>
</tr>
<tr>
<td>4</td>
<td>Antifungal therapy included in the initial combination</td>
<td>4 (1.4)</td>
</tr>
<tr>
<td></td>
<td>Add antifungal therapy after deterioration</td>
<td>5 (1.8)</td>
</tr>
</tbody>
</table>

AAAs, antianaerobic agents; NEC, necrotizing enterocolitis.

Figure 3 Duration of antibiotic therapy for stage II and stage III necrotizing enterocolitis (NEC) (days).
of antibiotics is needed based on expert consensus or updated recommendations.

The American Surgical Infection Society and the Infectious Diseases Society of America issued guidelines in 2010 which suggest that broad-spectrum antibiotics, including ampicillin, metronidazole, and gentamicin; ampicillin, metronidazole, and cefotaxime; and meropenem, may be effective for the treatment of NEC in neonates. In addition, when methicillin-resistant Staphylococcus aureus or ampicillin-resistant infection is suspected, the guidelines recommend the use of vancomycin instead of ampicillin. However, the use of gentamicin is prohibited by law due to the adverse effects of ototoxicity and nephrotoxicity in children under 6 years old. In addition, according to the investigations into antibiotic resistance in recent years, the levels of resistance to penicillin and ampicillin are extremely high, and these antibiotics are not used for the treatment of NEC in China. Foreign retrospective studies have reported that antianaerobic therapy has no added benefit with regard to mortality due to NEC, nor can it prevent progression to surgical NEC. Researchers also retrospectively evaluated the effect of broad-spectrum antibiotics combined with metronidazole in the prevention of the progression of NEC from stage II to III, eventually concluding that the addition of metronidazole did not prevent the progression of NEC. Therefore, whether metronidazole, ornidazole, clindamycin, and other antianaerobic agents should be routinely included in the treatment of NEC is still controversial, and a large-scale, multicenter, prospective study is needed.

The etiology of NEC remains unclear, and recent studies have reported that it is related to genetic susceptibility, intestinal immaturity, hemodynamic instability, intestinal microbial imbalance and inflammation. There are distinct microorganisms responsible for NEC outbreaks; thus, it is clear that NEC is not caused by one species alone. A wide range of pathogens are associated with NEC; among anaerobic bacteria, some toxigenic Clostridium strains, such as Clostridium perfringens, C. difficile and C. butyricum, are implicated as causative pathogens in NEC. Although the specific pathogens responsible for NEC may affect the selection of antibiotic regimens, there is no established standard to suggest a benefit from a wider range of antibiotics. Additionally, the intestinal microbiota in newborns are easily affected by the environment. Given the differences among NICUs and antibiotic strategies, the environmental flora are likely to differ, which may lead to different pathogenic bacteria causing NEC.

### Duration of antibiotics

Antibiotic therapy is variable. The use of antibiotics may not be effective if the duration of treatment is insufficient, while the prolonged use of antibiotics may result in an imbalance in the intestinal microecology and adverse consequences. However, there is no uniform global standard for the appropriate duration of antibiotic therapy. The Infectious Diseases Society of America suggests a duration of 4–7 days with adequate source control for complicated intra-abdominal infections, while 10 days is the duration recommended by the WHO. Some studies have indicated that limiting antibiotic exposure to 7–10 days might be optimal. Among the participants in this study, most chose 7–10 days for stage II NEC and 7–14 days for stage III NEC. There was no significant difference in the selected duration of therapy among physicians with different durations of experience, suggesting that Chinese doctors have a consistent understanding of the appropriate duration of antibiotic treatment.

### Adjustment of the antibiotic therapy strategies

Owing to the delay in receiving blood culture results and to low positive rates, the treatment of NEC in China is mostly empirical. This survey showed that when NEC was confirmed, carbapenems were the initial antibiotic therapy selected, followed by the addition of antianaerobic agents (including metronidazole, ornidazole or clindamycin) and glycopeptides. When the therapeutic effect was unsatisfactory, the proportion of doctors who chose to escalate therapy with carbapenems was 83.3%, and the proportion who chose glycopeptides was 20.9%. The proportion who selected antianaerobic agents as the initial antibiotic regimen was 55.2%; consequently, only 7.1% chose a combination regimen when NEC was exacerbated. When the treatment was ineffective, many physicians preferred to upgrade to carbapenems due to their stronger antibacterial effect on Gram-negative bacteria and due to their enhanced ability to act against anaerobic bacteria. In medical therapy for NEC in other countries, third-generation cephalosporins, carbapenems, and vancomycin are typically selected after empirical treatment with metronidazole.

According to the results of this questionnaire survey, the antibiotics selected for the treatment of NEC in China are most commonly effective against Gram-negative bacilli. When the therapeutic effect is poor, carbapenems are primarily selected, and some physicians choose to combine carbapenems with metronidazole, ornidazole, and other antianaerobic agents. At present, in China, due to the laws and various medication-prescribing preferences, there is substantial variation in the empirical antibiotics selected for the treatment of NEC; in particular, the treatment of Gram-positive bacteria may be insufficient.

In conclusion, there is no unified antibiotic treatment program for NEC, and it is necessary to carry out multicenter research to serve as the basis for the formulation of relevant guidelines for the antibiotic treatment of NEC in the future.

### Acknowledgements

We thank all the physicians who participated in the questionnaire in this study.

### Contributors

LB contributed to conceptualization. YH involved in data curation. ZZ contributed to writing—original draft preparation. ZW and LL contributed...
to writing—review and editing. YS was in charge of supervision. All authors contributed to the article and approved the submitted version.

**Funding** This work was supported by the Chongqing Municipal Administration of Human Resources and Social Security (Cx2017107), the National Natural Science Foundation of China (82001602), the National Natural Science Project of Chongqing Science and Technology Commission (grants cstc2019jcyj-msxmX0169 and cstc2018jcyj-msy4-X0027) and the Science and Health Project of Chongqing Health Commission (2020FYXZ217).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** This study received ethics approval from the Institutional Review Board of the Children’s Hospital of Chongqing Medical University (approval number 2020-22).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as supplementary information. Data are available on reasonable request.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

## Supplementary Table 1. The 20 combinations of antibiotics

<table>
<thead>
<tr>
<th>Combinations</th>
<th>CPs</th>
<th>PENs</th>
<th>BLIs</th>
<th>CAPs</th>
<th>GLPs</th>
<th>AMIs</th>
<th>AAAs</th>
<th>AFAs</th>
<th>Number</th>
<th>Frequency (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>49</td>
<td>19.6</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>42</td>
<td>16.8</td>
</tr>
<tr>
<td>3</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>37</td>
<td>14.8</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28</td>
<td>11.2</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>24</td>
<td>9.6</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14</td>
<td>5.6</td>
</tr>
<tr>
<td>7</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13</td>
<td>5.2</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>10</td>
<td>4.0</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>4.0</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>6</td>
<td>2.4</td>
</tr>
<tr>
<td>11</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>1.2</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3</td>
<td>1.2</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>3</td>
<td>1.2</td>
</tr>
<tr>
<td>14</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2</td>
<td>0.8</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>1</td>
<td>0.4</td>
</tr>
<tr>
<td>16</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>0.4</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td></td>
<td>1</td>
<td>0.4</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>0.4</td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>√</td>
<td>1</td>
<td>0.4</td>
</tr>
<tr>
<td>20</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>0.4</td>
</tr>
</tbody>
</table>

AAAs: Anti-anaerobic agents; AFAs: Anti-fungal agents; AMIs: Aminoglycosides; BLIs: Beta-lactamase inhibitors; CAPs: Carbapenems; GLPs: Glycopeptides; CPs: Cephalosporins; PENs: Penicillins.
Supplementary Table 2. Antibiotic duration of stage II NEC selected by physicians with different seniority levels (%(n/N))

<table>
<thead>
<tr>
<th>Duration (day)</th>
<th>&lt;10 years (n=48)</th>
<th>10-20 years (n=85)</th>
<th>&gt;20 years (n=151)</th>
<th>( \chi^2 )</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>2.1 (1/48)</td>
<td>3.5 (3/85)</td>
<td>0.7 (1/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-7</td>
<td>27.1 (13/48)</td>
<td>18.8 (16/85)</td>
<td>25.2 (38/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-10</td>
<td>56.3 (27/48)</td>
<td>51.8 (44/85)</td>
<td>51.0 (77/151)</td>
<td>6.401</td>
<td>0.570</td>
</tr>
<tr>
<td>10-14</td>
<td>14.6 (7/48)</td>
<td>23.5 (20/85)</td>
<td>21.9 (33/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;14</td>
<td>0</td>
<td>2.4 (2/85)</td>
<td>1.3 (2/151)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Fisher exact test.
### Supplementary Table 3. Antibiotic duration of stage III NEC selected by physicians with different seniority levels (%(n/N))

<table>
<thead>
<tr>
<th>Duration (day)</th>
<th>&lt;10 years (n=48)</th>
<th>10-20 years (n=85)</th>
<th>&gt;20 years (n=151)</th>
<th>$\chi^2$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>4.2 (2/48)</td>
<td>1.2 (1/85)</td>
<td>0.7 (1/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-7</td>
<td>20.8 (10/48)</td>
<td>17.6 (15/85)</td>
<td>16.6 (25/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7-10</td>
<td>58.3 (28/48)</td>
<td>51.8 (44/85)</td>
<td>58.3 (88/151)</td>
<td>6.217</td>
<td>0.589</td>
</tr>
<tr>
<td>10-14</td>
<td>16.7 (8/48)</td>
<td>27.1 (23/85)</td>
<td>23.2 (35/151)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;14</td>
<td>0</td>
<td>2.4 (2/85)</td>
<td>1.3 (2/151)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Fisher exact test.